Skip to main content
OpenTrials
Completed

NCT Number: NCT01225796

Study of Sodium Bicarbonate in Kidney Transplant Recipients

The purpose of this study is to compare the effect of sodium bicarbonate versus no sodium bicarbonate treatment on urinary ammonia levels and urinary transforming growth factor-beta1 (TGF-beta1) excretion in renal transplant patients with low-to-normal serum bicarbonate levels (20 - 28 mmol/L).

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Utah

Salt Lake City, Utah, 84132, United States

About this study

Renal allograft survival ten years after transplant is only about 50%. In people with non-transplant chronic kidney disease (CKD), sodium bicarbonate treatment seems to delay progressive decline in kidney function in those with low serum bicarbonate levels (metabolic acidosis). This may be because sodium bicarbonate reduces renal ammonia production and hence fibrosis. Observational evidence suggests that people with CKD and low-normal serum bicarbonate levels might also benefit from sodium bicarbonate treatment. TGF-beta1 levels seem to be an important predictor of chronic allograft nephropathy, and alkalinizing agents may have an effect on TFG-beta1 excretion.

Retrospective analysis of participants in the African American Study of Kidney Disease and Hypertension showed the lowest risk of CKD progression was among those having baseline serum bicarbonate levels in the range of 28-30 mmol/L. Recent studies in people with pre-transplant CKD have suggested that increasing low serum bicarbonate levels (< 22 mmol/L) with alkalinizing agents such as sodium bicarbonate and sodium citrate may reduce CKD progression.

Design: this is an open-label randomized study testing the effect of a six-month intervention with sodium bicarbonate 650 mg orally thrice daily versus no sodium bicarbonate treatment on renal ammonia excretion and urinary TGF-beta1.

Visits will occur at baseline, 3 months, and 6 months. At each follow-up visit, the study coordinator or principal investigator will review a medical questionnaire with the participant and collect a sample of blood and urine for analysis of urinary TGF-beta1, metabolic panel, pH, urinary net acid excretion, urinary bicarbonate and urinary ammonia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Renal transplant recipients
  • Age 21-75 years
  • Six months since the time of the most recent transplant
  • Serum bicarbonate 20-28mM on the two most recent serum measures with the last six months
  • Stable creatinine

Exclusion criteria

  • Systolic blood pressure > 140mmHg
  • Diastolic blood pressure > 90mmHg
  • Known ejection fraction <50%
  • Clinical diagnosis of heart failure
  • Use of >3 antihypertensive agents
  • > 1+ edema
  • Use of alkali in the preceding 3 months
  • History of noncompliance with clinic visits

Treatment and study plan

Sodium bicarbonate

Drug

Sodium bicarbonate 650mg by mouth three times daily for 6 months.

Primary outcomes

  1. Urinary transforming growth factor-beta1

    Time frame: 6 months

    This is considered a surrogate marker of chronic allograft nephropathy (tubulointerstitial fibrosis).

Secondary outcomes

  1. urinary ammonia excretion

    Time frame: 6 months

    a component of urinary acid excretion

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Official study title

Randomized Trial of Sodium Bicarbonate in Renal Transplant Recipients With Low-normal Serum Bicarbonate Levels

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Oct 21, 2010
Registry last updated
Apr 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.